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stucly, Three hundrecl twenty.flve patlents[277AF/48AF1; 84% male: avemge 
age • 67 yeam; dumtlon of AF/AFI, R wesks-7 months; NYHA: I ,  28%, II 
ù 64%, III - 8%] wem randomlzed to 1 of 4 treatmant gmups: 
Dofetltldo 125 mag, 250 mag, 500 mag, er placebo BID, The numher of 
pstlentl who aehlevnd N.~R allor 3 dlys of oral doslng wem ss follows: 
plsoebo 1/82 (1%), dofetlUde 125 mag 5/74 (6%), dofatlllda 280 m~ 8/79 
(t0,1%), dofetlllda 600 mag 23/71 (32%), Advoma arrests wem batanced 
aeron tmmlment gmups, No tomsdss ner daaths o~urmd, 
Con¢luslon: We oonclude that oratly ~dmlntsfere(:l dofatlllde at 500 me0 
0lD Il effo¢tlvo and safe In convarllng ehmnl0 atrtal flbrlllstlonffluttar fo normel 
slnul dlylhm, 
10:45 
~ IntrlvengUl Vlnlul In Rlolnl Proplfenono Olgoxln 
Onnt Atdld Flbtlllotlon. A PlllOebo-eontmltN, 
Rlmdomllmd 81udy 
L, Btlm~nl, On tJetmtf of R4FIT.3 Inv~fl~tom; $, Flllt~oo Net~ Hospltal, 
~n( / :  Intmv~nouo pmp~fenone (Pmp) h{ls been ehown to eJff~tlv~ly 
metom slnus ~hythm In moent onsal +tilgst flbflll+ltton (AF), whlle tha alfto+lW ot 
Iv dl~o~in (Olg) hu  b~n quolltlonod, Howovor, ~ dlmot ~oml~dllon mono 
thxa dn~lll i~nd plaoebo (Pl~le) le still I~~klng, 
Malfto~: Oßa hundr~ tw~nty lhmo pte wlth AF lasttn9 <7~ hm wem 
mndomlzed 1o silber Iv Pmp (g mg/Kg, 41 p~) or Iv O19 (0,5 mg, 40 ptel) or 
Plao (4~ pte), After 1 hour, non,eonvened Pmp o~ D~ 9 pts wem ewltohed to 
lho oll~r d~~l, whlll non,oonv~rt«] PIke pt~ wem mndoml~ed to nlthm iv 
Pmp er Dt9 and monltomd for a lurthet heer, 
R~uffa: A~r  the first tmatn'~nt, 20/41 (49%) Pmp pts wem onrdlove~~d, 
venlus 12/40 Ot9 pta (32%) and 6/42 Pilz0 ple (14%), The table sparte the 
mlldlve e111¢l~y (RE) of the dnlgs oslculMad by IOglStlo mgmsslon anatysls, 
Am~ng the 47 pt~ mstant to the filet t~tmant who wem 8wlt¢hed to the 
altem•tlve dmg, Olg was effectlva in t/20 pts (5%) nnd Pmp in 12/~7 (48%) 
pla (p < O,OS). tn the 35 w0n-convel1~l Pl8e p~ elloeafed to ~n ~¢tlve dmg, 
slnus rhythm was obtalmKI in 10/19 pts (53%) by Prop and in 1118 pts (5%) 
by Dl9 (p < O.OS). ConsltJeting all the 118 pts who 11~"elved a dn~g as a first 
~tl~l tmalment, ~onvenllon rotes wem 50% (30R0 pl~) wlth Pmp and R5% 
(14/S8 pt~) wlth Olg (p < O,0t, C,I, 95%1,2-3,4), No etgnifi~ant stde efle(:ts 
wem obsonmd In any pts. 
RE C,I, 95% p 
Prop vs Plac 3.41 1,53-?,63 .0.01 
I~g vz PI~ 2E7 0,9e-,~.40 NS 
Prop va 0t 9 1 50 097-2,59 NS 
Conc/usk~: In m,.-'ent onset AF Iv pmpafenone festeres s~nus mylhm 
mom effectlvely than etther plac'flbo r tv dtgoxln, 
11:00 
~ Effi©ll¢y and Safety o1 Intmvonous Flecslnlde 
Compamd to ami  Qulnldlne tor  Convemlon o1 Acute 
Atdld Flbri l latlon (AF) to Slnus Rhythm In Patlents 
P~tlreated Wlth Intravenous Metoprolo l  - The 
FLEQUIN Trlal 
M.O, Hallr~n, A. Pulkklnen, J, Mustonen, M, Puhakka, M. Huftunen, 
S, Paskklnen, L, l~rssanen, M, NIsslnen, J, Melln, T, OIll, Dept, of Medlclne. 
Kz~WO Un~~erstly I'fOS~tal, Kuopto; 4 Central Hospltats, Easfem, Finland 
Ob~ves:  We sfodled the efficacy and safety oi i.v. flecalntdo compamd 
wlth erst qulnldlne for the convemion of saufe AF after Lv. metoprolol was 
glven to Iower ventrlcular ufe, 
~¢k~ound: Eftectlve and safe treatment oi saufe AF is needod in the 
emelgency team. A detay in conversion to slnus rhythm (SR) prolongs the 
hosplfel t~tment and Incmases costs. 
Methoats.' A randomiseck double blind comparison between flecainide (2 
mg/kg wlthtn 30 min.) and qulnldlne (200 mg up to 3 tlmes 2 hr apart) was 
perfon~ed In 163 patlents wlth acufe (<48 hours) AF after metoprolol was 
given openly. 
Resutts: SR was restored within three hours in 45 (54"/0) of the 83 patlents 
In the flecainldo group and in 24 (30%) of the 80 park nts in the qulntdine 
group (p = 0.0018). DC cardlovemion was needed in 23% and lq% of 
patlents (14,S.), and the medien detays to SR ware 0.8 hours and 4.1 hours 
in the fleealnk~e end quintdine gmups, respectlvely (p < 0,001), The medien 
hosplfet sfe:, ~-I p~tients not needing DC ~'~rdloverslon a d pmlonged hospital 
stay (>48 ht) ~^'a~ 6,4 hr in the flecainide group and 9,4 hr in the quinidine 
group, (p = 0,012). Asymptomatic pauses of 3-9.8 seconds wem found in 
ambulstoty ECG recording of 8 patients in the flecalnlde group and of 7 
patients in the quinidine group. Two patients in the flecainido group had a 
shorl lasting circulatory collapse. 
Conclualons: Fle~alnlde actod mom rapldly In mstodn9 8R than qulnldlne. 
Both druga wem safe for the tmalment of outpatient~ in the emergeney 
room, I,v, metopmtol was a safe pmtmatment for petionts tmated wlth etther 
flecalnlde or qulntdlne, 
11:15 
~ A©ut~ Atrlol Flbrl l lat lon' Hlgh,l~N IV Amlodorone 
Fu l l i to tu  Convemlon to  Nofmol  81nus Rhylhm. 
When is it Ne~ss l ry?  
G, Cottor, E, Coltet.Melzkor, E. Kalulki, A, 0tat, Y, M01~kovltz, I Ulk~ky, 
M, Komn, R. Zt|ldensfeln, A, Gollk, Amf.P~n~#ft Me(J~al O#nt~, 
tarne/ 
The rate of epontsneoul ¢onwrelon of ~ Iztfial fibd!lat!on (A« AF) to 
normal sinus dlythm (NBR) le high and not affo¢tod by Iow ¢lole lmto¢lemee 
(Am,) trimtnl~nt, We lvaloltt¢l high.deN Am, in 1ha tfelftllent et A~D AF. 
Metho~: Etghty pallanta (ptl,) wlth parox~mat AF, ~ for A~~ AF 
(,~48 h) wem random~ed to m¢elve for 24 t~um: (1) Group A, (n = 40); 
Pl~l~bo (R) Group 6, (n ~ 40): ~H1tlnuou8 IV Am, 120 mg/h~f (tl~M 3 9), 
Group A pta, not oonvolttn9 to NSR wtfhin 24 bi' wem ommled ~ to Am 
Ihempy, All p~, meeWed OIgoxln, 
Resut~; Basellna pulea was 1~7 ± 19 beafi/min, and ± al beatMmm, in 
gmups A and B, in group A, 2? pilz, (67%) (xmveltod 1o NSR w. 3B (90%) in 
group B (p .  0,029), ~nty. fhte of 27 (93%) pls, ¢~~,e~nQ SlXmtaneoulW 
(in group A) have ¢onverted within t 2 hmlm, Eleven pts, (85%) in t~ B not 
+co~~!11111g on plaeetlo have c~nvetted after being ~ O~ef to 
Am, t~tment, Flnally, 0 pt~, (in both gmup~) dtd not colwe~t on 
Am,, 3 ~ve~KI  a~tot ele¢td~l ~rdlovefetoß, ~ all 6 wem in ch~ AF 
after 1 month, In p~, still In AF ~fter 8 houm et tmatme~, the putse fete 
deemased to 114 :E 20 txlafe/m~n, ingroup A v*. 83 ± 15 beets/min, tn graue 
B (p = 0.0014). No advefse event~ mquldng tmalment O¢¢UnIKI in (Imu~ B 
pts. 
t 
Cot¢lusk~n: IV high-dose Am. tmatment (120 mg/ht) is safe and lacilitates 
convemlon O1 Ac AF to NSR. Spontaneous conve~sion commonty occurs 
wlthln 12 hours, themtom, high-dose Am. may be resen~ed for pts. mquiring 
rate control, tang form Am. tmatment er not convefling within 12 heus. Pts 
resistant 1o high-dose Am. am at high risk of developing chronic AF. 
11:30 
~ ~ 7  Class III Drugs for  Suppress ion  of  Recurrent 
Symptomatic Atrktl F ibdl lat ion 
G.E. Kochiadakts, N.E. Igoumentdis, M.E. Marketou, M.C. Solomou, 
E.M. Kanoupakis, P.E. Vardas. C.aro'/ofogy Dept., Hersklion University 
Hospital. Cmte. Gmece 
Background: In this comparative trist, we examined the efficacy and safety of 
amtodamne and sotatol in maimaining nom~t sinus rhythm in patients (pts) 
with retractonj atdal fibfitlatton. 
Methods: Seventy consecutive pts (39 men, mean age 63.1 ± 9 years) 
,ver: randomized into two clinicatly similar groups: 35 received amiodamne 
and 33 sutalot. Pts with ejection fractton <40% er clinlcatly significant heal~ 
disease wem excluded, The amiodamne dosage began with 800 to 1600 
mg/day for 7 to 14 doys oralty and was then fepered over 7 to 12 days, gen- 
erally to 200 mgtday. The sotatol dosage was 160-360 mgtday, as *.olo=t~d. 
Fotlow up clinlcai evatuations wem conducted at 2 month intewals tor the first 
6 months and at 3 month Intetvals thereafter. The propodion of pts mmaining 
in slnus rhy~hl~~ was calculafed for the two groups using the Kaplan-Mefer 
method. 
Results: Ten o1 the 35 p~ on amiodamne developed atrial fibrillation 
during the 12-month obsewation period, compared to 21 of the sotalol group 
(p = 0.008). Progmssion to atriat fibrillation was faster in the sotaloi pts 
(p = 0,012): after 6 months, 77.4% of amiodamne pts remained in normal 
sinus rhythm compared to 54.3% of the sotalol pts, whife at 12 months the 
respective percentages wem 71% and 40%. Sex, age, left atdat size and 
atrial fibrillation type had no significant effect. 
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Cor</us~~: Amto¢l~one I~ mom (ffh~-tlve than =ota~ In ttte pre~mlk~ 
of mcum~ Wmptoma~ arr~ fg~latloa, poss~ly, because of the d~ferent 
mod~ of a~on ol ~ lwo dmgl. 
11:45 
~ Effeot of  Choml~l  vs  ~ 1  o f  C~rdloverolon 
Chmnl~ A ld l l  FI I I f l lkdlon ou L i f t  Alv~ll 
FU-ù~lm 
B Nm~ùo, G, Ct~w, P-, MonW~d, L Mwm, Om' m'¢a~k~W ~ 
mm~ ~ ~ m~mm to ~ mode ~ GV and m mm ~ m pm 
ù~m~m~  (ccv) Nn  emm,~ Cv (~CV), 
m a ~  ~ and L.A ~ ~ (8C) ton~ m ~ p1~ 
tmatt~ i ~  m ~ ~o I~CV. M pls wem ~ 
wM1 ~ k~ at least 4 v=0elut and none had Mmd t~~ml~S. 
(~~,ro), 40 p~ u~lenve~ ECVw~ ~ of =nu= ~ a~d 2 pts 
we~ e=duded ~ me =udV as [x~h CCV and ECV was un~---'~~~~-- L~ 
a ,~4,). ~~~e w~e no mB~ca~ dmemnc~ be~wmn me 2 ~mms kùr a~.  
gendm, k~! a~na~ ze, EF, NYH~ dass (</= ù), amx~md ca~lopa~m and 
du~lmn ol N=. 
CCV (n, 12) ECV (n - 40) 
LAA.E (¢m~se¢) LA,~F (o~~~ec) SC LAllE (cm#me) ~ (¢m/l~-~ SC 
43:,*.16- 47.13 0-0.4:!" 40:1:18 45¢15 11±12 
~-CV 27,8" 34 ± 10 ~ 1.4 ± 1.5 r ~B ± 10" 31 ± 16" 1.7 ± 1.4" 
• lYe vs post-:p «O.O05;'l~eVSpom~:p < O.Ot; CCVvsECV: p ns 
F~~st CV peek E ware, peak A w-~,  E/A m~o, VTI A ~~ve, vlrl E ware 
and VTI A wave/Tof Vllwece siml=r fo¢ CC'V a~,~d ECU/IFoups. 
~ - ~  CV ol chmaic kF. whefl'~r CCV ~ ECV. is as~" ia~l  ',~h 
a =,a,,;;;;a,~; ¢leoease m I.AA mechanic~ ~ In pts wfflt chmrm AF of 
> 5 we~s dü,-~,~,-, mein is no e~;~-,c~ Ihat EGV pmduces gma~ posl CV 
l~t atnal and LAA dys~nctma mml CCv. 
Cons iderat ions  in  the  O iagnos is  and  
Treatme~ o f  Acute  Myocanllal I n fa rc f lon  
Wednesday,  April 1, 1998, 10:30 a.m.--Noon 
Georg ia  Wodd Congress  Center,  Room 261W 
10:30 
The Rom of Room Ecllocmdk)  raphy hl 
~n~~~ PaUen~ W~h Ch~t  Pah~ at h~e~~d~e _ 
Risk for  Acute Myocmdlal  Infarctlon: A Sub4~mb'y of  
CHEER 
M Allen, J.K. Oh, M.E. Farkouh, A.R Zmsmeister, P.A. Smam, J.B. Sewa~, 
G.S. Reeder. Mayo ~ Roc-/lester, MmnesoM, USA 
Back~ound. The pmdic~m value ol a cliagnos~ test ~'1~,~ds on 8~e PoP" 
ulation being sludied. Nthough 2-D echo has been shown to be useful in 
identitytn9 patients (pts) with chest pam who subsequen~ develop myocar- 
dial infamtJon (MI). the role of erno~jency mom (ER) echü in the tnage of 
intetmed/ate nsk pts is not known. 
Me~~~~s: Two-D echo was ptospectively performed in 178 lOtS w~th chest 
pain at intermediate nsk (by the AHCPR guidelines) for acute MI. Echo 
was performed in the following the enrollment in the CHEER (CHest pann 
Evatuation in the Emergency Room) stndy. 
Results: Median age was 59 years and 56°/= wem male. ECG was abrmr- 
mal in 52%, pmvious MI was present in 17%. Echo showed abrmm'~ wall 
mofion in 71 pts (40%). The initial CK-MB was elevated in 5 pts. Dudng hos- 
pitalization, 7 pts (4%) developed acute MI and 6 of them had abnormal wall 
motion (sensitivity of 86% and positive predictive value 8%) and abnormal 
ECG. Abnormal wall motion on 2-D echo was univadately associated with 
acuts MI (p < 0.03), but was no Ionger significant in predicting acute MI after 
adju':ting for ECG and CK-MB. 
Conclusion: 1) Intermndiate risk 10rs have a Iow incidenCe of MI. 2) Wall 
motion abnormafity is univariately associated with acute ML 3) However, 
abnormal echo lacks the incremental value over ECG and enzyme data. 
4) Two-O t~¢ho m It~ ER it not ¢ tk~ u~oful m i:~ wflh ¢t~lt IN~ ~ 
intermedlate ftlk. 
10:45  
Wh~ ~ ~ d~ ~ m~m#m tm tmm t~~tmd m P~ i~ ~ ~ ~ 
m~my m ~ m~mn9 ~ ~ ~,  ~ m ~ mm,~q~ mltùy tm n~ Imm 
hm tmm mmm~ » t~ mm~ taxi m~xl m ~ ' t~ l  raùdm" m ~ 
~ am~y In m MI ~m ffmom~m/#~m~ 11~g~ ~ t~ tmmb wmm 
m d~mm~e ~~mg~ m m~~~~ amùy km ~m~ w~h ~~~mm 
m mm m (m~ml oMmy flow m m ~,  The m mmd~d fo~ 
tO0 ma~s, m a ~m~! ~ ,  ~ eow (GTFC) m ntm,~~ ramm 
mmm,~ W~ mm~ù m mm~ mm m ramm mo~,~ùm,wmm 
(34.9 + 16.7VL 3~1 + !&0, n~252,p « G ~ ,  When lk~w~m 
~e mm~md cUlpm a~y ~ 00 mmu~ a~190 mm~l ,  n0~ul~ 
am~y ~ ~ ~ ~3"~. ( '~0 + t?.7 vo. 313 ± 18,?, a ~an~e o~ 
4.68 + 11.1, n~, 100, p < 0.0(K~~). ',M~en llow dld not Imlm~ m Ere 
flow be~t~Nm (iO R~~ßul~s and g0 ff;nukm (33.8 • 15.4 vlk 33.3 ~ 16.0,11 
chmm~ ol 0.S ± 9.2, n = 120, p = 0.,~). 
~ Cnan~s m non-~p~ m now am a~a~~ 0o ~m0n m 
te mo cu~t  anmy. 
11,.-00 
Rmmlul~n ~ ST41qmmt Bwl lkm l0  ~ 
A,,t~ ~ Oor A=m U, UWm=«mU ù~m=U«, 
IPvtdt¢ll  Ou l l :eO:  A 6LB'lO-ilN Sl lboludy 
RD. ~dm~ RD. VaX, E.M. Ohman, «S. W~mT, M.W Kù,~V, 
p.w. Am~smmg. H.P. Ipan~gWùm, W.W. Weav~r, W.B. Garer, R.M. Ca~. 
Dl~m Crm:a~ Rasaw~~/m~el~~ Olallam, NC U«A 
Ruofution ot ST<~gment e~~~,]  180 mln after ~ fo¢ scum MI 
pù~k, ts acum ou¢omas, t~t ~ a 90-mm ECG ~s a~m pmd~ö~~ em"m ~m~r- 
ven«on m possa~e. Thm sut~ndy enm~ed I ~3  pts Imm m inmmatmnal tnal 
of alteldase rs. m, tel~ase lmawtlnt wlfltfn 6 h of MI. ECGs m otlkled M 
bas~m~ g0, ard 180 mm after ~¢s. The sum ot me ST-segment resolution 
a~ gO and 180 mmwas c a ~  as <30%, 30%-70%, m >70% msolved 
~mm ~ We compamd groups m (mmm~e It ST ruolu~~ gO mm 
was as l~~liclM~ as at I~0 min. 
30-dL-y Oldoomes 
S l "m 
«30% 30-70% >70% p 
go n~n ~ 7.5% 3.0% 2.6% 0.01 
De;im 10.8% 6.0% 3.1%0 0.01 
180 mm ~ 8.4% 2.9% 3.4% 0.04 
Deal~ 14.3% 6.5% 3.4% <0.0001 
Co«¢~~=~~n.. pe«s~st~~; ST-segment elevaUon as eedY u 90 nm aflm 
thr0mbofysis ts i ~  important, as is elevatton Pemstlng at 3 h°um. 
• r~ data shouk:l he~p ide~~~fy pts who may benefit horn oe@ ~ -  
Tmatment ~~~,gms shotdd be ~ for pts w~ conth~x d -~r'wgment 
elevatk~ after ~ .  
11:15 
5 -~ Redu¢tlon in ~n Iß l  Hemo~ Ano¢l l f l l ld  
Wùh Immedlllte Beta-Bkxdmr Thenmy kl Patlmts 
with Acute k~Ao¢anJial Intamtion lnreanted With 
Tissue Plasminogen Acf l~~ü[  
H.V. Barron, A.C. Run¢Be. J.M Gore, J.H. Gutwltz, J. Petwtey. Un~ of 
Califomla, Sah Fra~~c;scü and ~ inC. Sou'fh Sah F'rm~~~;ü. 
Califomia, USA 
B a ~ :  In the Se;üFù.3 of an acute myocam'ial infarction (AMI), 
beta-blocker therapy reduces the inc~enco f relr~arctJno and reCuff~~t ¢hest 
pain in patients receMng t-PA. Pmviously published data sugge~ that such 
therapy may also reduce th~ rate of im.T:cr.~'fial t temor~ ;.iCH). 
